About Us
Allera Health Products, Inc. is dedicated to providing innovative products of the highest quality that are based on sound scientific research.
Allera Health Products, Inc. develops supplements that enhance the immune system and drugs that help fight illness and disease. Headquartered in St. Petersburg, Florida, the biotechnology company was founded in 2005.
The company's first product, ImmunExtra™ comes to market after more than 15 years of rigorous research on the pinecone extract that is the basis for Proligna™. Extensive research indicates that pinecone extract optimizes immune cell activity to help the body combat germs and viruses that may cause illnesses.
Allera Health Products holds the exclusive license for Proligna™, a compound developed by scientists at the Tampa Bay Research Institute in St. Petersburg Florida. ImmunExtra™ is the first product based on this breakthrough compound; research continues to determine its true potential.
CEO Frank Tufaro, Ph.D. is leading a team of more than a dozen of the foremost experts in science, manufacturing, and marketing.
ImmunExtra™ is produced in the United States by Allera Health Products, in facilities certified by the NSF (National Sanitation Foundation). These facilities employ Good Manufacturing Procedures to ensure product quality and consistency.
CEO Frank Tufaro, Ph.D. and CEO is a former professor of microbiology and virology at the University of British Columbia. During his 17-year tenure, he published extensively in the areas of virology and cancer.
Frank was one of the original founders of Neurovir, Inc., a Vancouver-based biotech company with a mission to develop herpes-simplex virus oncolytic vectors for treating cancer. Frank initially served as Chief Scientific Officer, where he managed all aspects of drug development, including FDA interactions and contract manufacturing. He then served as CEO, during which time he negotiated and executed the successful merger of NeuroVir with MediGene AG, a public company headquartered in Munich, Germany.
Following the merger, Frank was appointed the Managing Director of the U.S. subsidiary of MediGene AG. In that capacity, he hired and led a team of 15 Directors and VPs, including representatives from manufacturing and process development, pre-clinical, QA/QC, regulatory, clinical, and business development. Within 18 months, he developed MediGene, Inc. into a fully integrated drug development company of 55 employees located in two facilities in San Diego.
From MediGene, Frank worked with several biotech start-up companies to develop successful financing and product development strategies.
Frank remains active in both the business and scientific arenas. He serves on the Scientific Advisory Boards of several public and private companies.
TBRI site